P
atients with cancer often exhibit heterogeneous responses to anticancer treatments, and evidence indicates that response is determined in part by patient-specific alterations in the somatic cancer genome and changes in gene expression 1 . Cancer cell line studies have long been used to test the efficacy of therapeutic agents and to explore genomic factors associated with drug response 2, 3 . A number of studies have searched for gene expression signatures predictive of response; however, most only tested a limited number of genes, a small panel of drugs, or assayed drug response in a small number of cell lines 2, 4, 5 .
Results from two large-scale pharmacogenomic studies-the Cancer Genome Project (CGP) 6 and the Cancer Cell line Encyclopedia (CCLE) 7 were recently reported in this journal. The CGP tested 138 anticancer drugs against 727 cell lines whereas the CCLE tested the response of 24 drugs against 1,036 cell lines (Extended Data Fig. 1 ); of these, 15 drugs (Extended Data Fig. 1a, b) and 471 cell lines were tested in both (Extended Data Fig. 1d , e). There was overlap between both data sets for mutations in 64 genes (Extended Data Fig. 1g ) and expression of 12,153 genes (Extended Data Fig. 1h ). The overlap allows assessment of consistency between these independent data sets and the potential to infer genomic models predictive of drug response.
We downloaded, curated and annotated the genomic and pharmacological data from the CGP and CCLE studies (Methods). We first compared expression profiles between the 61 biological replicates in CGP and observed very high correlation (median Spearman's rank correlation of 0.97; Fig. 1a ), indicating excellent reproducibility within the same study.
We then compared gene expression profiles of the 471 cell lines shared between studies. Despite the use of different array platforms (Affymetrix GeneChip HG-U133A in CGP and HG-U133PLUS2 in CCLE), the expression profiles of identical cell lines were significantly better correlated than between different cell lines (median correlation of 0.85 versus 0.34 for identical and different cell lines, respectively; two-sided Wilcoxon rank-sum test P value ,1 3 10
216
). For 467 cell lines, the most highly correlated gene expression profile was with the same cell line; only four (MOG-G-CCM, SNB19, SW1990 and SW403) were more highly correlated with another cell line (Fig. 1b) . This small discordance between the CGP and CCLE is probably due to experimental artefacts, measurement error, or divergence of the four cell lines. We tested consistency based on 6 and CCLE 7 studies. a, Box plot representing the Spearman's rank correlation coefficients of the biological replicates in CGP, and identical and between different cell lines from CGP and CCLE data sets. The box and horizontal bar within represent the interquartile range and median of the correlation coefficients, respectively. The whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box. b, Heat map representing the Spearman's rank correlations between gene expression profiles of cell lines; the order of cell lines is identical in rows (CCLE) and columns (CGP). the tissue from which the cell line was derived ( Supplementary Fig. 1 ). We found the highest correlation with cell lines from the urinary tract (median correlation of 0.87) and the lowest for those of the upper aerodigestive tract (median Spearman's rank correlation of 0.79).
We compared the reported presence of mutations for 64 genes in the shared 471 cell lines and found better agreement between identical cell lines than between different cell lines (two-sided Wilcoxon rank-sum test P value ,1 3 10 216 ; Extended Data Fig. 2 ), although not perfect agreement (median Cohen's kappa (k) of 0.65), which might be due to the different sequencing platforms and software used to call genomic variants in the two studies. Agreement in mutation profiles was higher in pancreatic cell lines, although the difference was not significant (Supplementary Fig. 2) .
We then compared drug sensitivity phenotype measurements. In the CGP 6 study, drug screening was performed at two sites: the Massachusetts General Hospital (MGH) and the Wellcome Trust Sanger Institute (WTSI). As a control, camptothecin, an inhibitor of DNA enzyme topoisomerase I, was screened at both sites using the same experimental protocol in 252 cell lines. The IC 50 (concentration in micromolar (mM) at which the drug inhibited 50% of the maximum cellular growth) 8 for camptothecin had significant but only fair correlation (Spearman's rank correlation coefficient (r s ) 5 0.58. P value 5 1.5 3 10 223 , Extended Data Fig. 3 , see Methods for definition of 'fair' and qualitative description of correlation).
We compared drug sensitivity measures between CGP 6 and CCLE 7 for 15 drugs (Extended Data Fig. 1a , b) tested on the 471 shared cell lines (Extended Data Fig. 1d , e). Both CGP and CCLE measured cell line drug sensitivity using IC 50 and AUC (area under the activity curve measuring dose response), also referred to as activity area 8 ; however, the two studies used different experimental protocols (summarized in Supplementary Information). Differences include the pharmacological assay used, the range of drug concentrations tested, and choice of an estimator for summarizing the drug dose-response curve.
In both studies, the IC 50 could not be estimated in many cases, as drug concentration necessary to inhibit 50% of growth was not reached. In CGP, IC 50 was estimated using a Bayesian sigmoid model for drug response. In contrast, CCLE reported the maximum concentration for inactive compounds (referred to as placeholder values) rather than the extrapolated IC 50 . AUC measures do not require extrapolation and can always be estimated from the dose-response curve.
For each of the 15 drugs assayed by both CGP and CCLE studies, we ranked the response of the 471 shared cell lines (Fig. 2a) and computed Spearman's rank correlation coefficient (see Methods) for the reported IC 50 (Fig. 2b) . We found a single drug, 17AAG (an HSP90 inhibitor), with moderate correlation (r s 5 0.61; Extended Data Table 1a) , and another, PD0325901 (a MEK inhibitor), with fair correlation (r s 5 0.53; Extended Data Table 1a ) between studies.
To test whether extrapolation decreased the correlations between studies, we filtered out all IC 50 values exceeding the maximum tested drug concentrations. We observed only small increases in correlation for PLX4720, PD0325901 and paclitaxel and decreases for 17AAG and AZD6244, although the number of measurements was small (Extended Data Fig. 4 ). We also compared reported AUC measures (Fig. 2b , Extended Data Table 1b and Extended data Fig. 5 ) and found that only two drugs yielded fair correlations (17AAG with r s 5 0.58 and PD0325901 with r s 5 0.55).
We compared correlations computed from IC 50 and AUC (Fig. 2b ) and found that AUC is more concordant between CGP and CCLE (median Spearman's rank correlation of 0.28 and 0.35 for IC 50 and AUC, respectively) 4  5  6  7  4  3  5  3  4  5  6  7  8  6  7  8  9  5  6  7   8  3  4  5  6  3  4  5  6  7  8  3  4  5  6 b, Bar plot representing the Spearman's rank correlation coefficient for IC 50 and AUC drug sensitivity measures; significance is reported using an asterisk if two-sided P value ,0.05.
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but that the difference was not significant (two-sided Wilcoxon signed rank test P value 5 0.3). The vast majority of drugs yielded poor concordance (r s , 0.5) for both IC 50 and AUC, which suggests that the lack of consistency of the drug response cannot be solely explained by the choice of the estimator of drug sensitivity. We tested whether drug response correlation depended on tissue source. We found that both IC 50 and AUC measures tend to be more consistent in cell lines originating from urinary tract ( Supplementary  Fig. 3) ; this difference is significant for AUC (two-sided Kruskal-Wallis test P value 5 0.024; Supplementary Fig. 3b ). However, owing to the small number of urinary tract cell lines (10) , only three drugs (PD0325901, nutlin-3 and 17AAG) showed a statistically significant moderate correlation ( Supplementary Fig. 4) .
In addition to IC 50 and AUC, we also compared sensitivity using the waterfall method described in the CCLE study 7 . For each compound, we considered the shape of the rank-ordered plot of response values (logtransformed IC 50 or AUC) to assign cell lines into resistant, intermediate and sensitive classes (referred to as drug sensitivity calls; see Methods). Such drug sensitivity calls were estimated from IC 50 and AUC values and compared using Cohen's k (see Methods). Again, the drug sensitivity calls for both IC 50 and AUC estimates (Supplementary Tables 1 and 2 ) had a poor agreement between studies (k , 0.5; Supplementary Fig. 5 ).
Despite the discordance in drug sensitivity measures between CGP and CCLE, we tested whether the association between drug response and genomic features might be consistent across data sets. This is important because the identification of genomic predictors of drug response was the primary goal of both the CGP 6 and CCLE 7 studies. We estimated gene-drug associations by fitting, for each gene, a linear regression model including gene expression as predictor of drug sensitivity, controlled for tissue source (see Methods). Linear models were fitted using both IC 50 and AUC measures (Supplementary Data 2-5). Here too, we observed poor correspondence between studies; the best correlation with IC 50 data was observed for PD0325901 and 17AAG (r s of 0.36 and 0.38, respectively; Fig. 3a , Supplementary Fig. 6 and Extended Data Table 1a) ; for the vast majority of drugs, correlations were slightly better when AUC measures were used to estimate gene-drug associations, but the best correlation was still poor (r s 5 0.46 for PD0325901; Fig. 3a , Extended Data Table 1b and Extended Data Fig. 6 ). Although correlations significantly depended on tissue source (two-sided Kruskal-Wallis test P value ,0.006), only drugs screened in haematopoietic/lymphoma tissue and urinary tract yielded slightly higher correlation than all tissues combined for both IC 50 and AUC ( Supplementary Figs 7 and 8) .
We tested whether these poor correlations could be due to genes unrelated to drug sensitivity by focusing on genes statistically associated with drug sensitivity (false discovery rate (FDR) ,20%) in at least one data set. Overall, whereas the correlations were better than those computed using all genes, they were still low. For IC 50 , only AZD6244 and 17AAG yielded a moderate correlation (r s 5 0.65 and r s 5 0.63, respectively; Fig. 3b , Extended Data Table 1a and Supplementary Fig. 9 ). Using AUC and this subset of genes, we found that PD0332991 had a fair correlation, and five drugs had a moderate correlation between studies (PD0325901, AZD6244, nilotinib, 17AAG and nutlin-3; Fig. 3b Supplementary Figs 11 and 12) .
We recognize that activation of drug response through specific gene functional classes may be more predictive than individual genes. We 6 and CCLE 7 data sets. Significance is reported using an asterisk if one-sided P value ,0.05.
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therefore used the previously computed gene-drug associations to rank genes by the significance of their association with drug sensitivity and searched for over-represented Gene Ontology (GO) terms using preranked gene set enrichment analysis (GSEA) 9 . We compared the normalized enrichment scores computed for CGP and CCLE for the 15 drugs screened in both studies (see Methods).
For IC 50 , there was poor correlation of GSEA enrichment scores for drugs, except for AZD6244 and PD0325901, which yielded fair correlation (r s 5 0.63 for AZD6244 and r s 5 0.68 for PD0325901; Fig. 3c , Extended Data Table 1a , Supplementary Fig. 13 , and Supplementary Data 6 and 7). When using AUC, two drugs yielded fair correlations (nilotinib and 17AAG), AZD6244 yielded moderate correlation, and PD0325901 yielded substantial correlation (r s 5 0.76; Fig. 3c , Extended Data Table 1b We repeated the analyses, this time focused on the GO classes that were statistically significantly enriched (FDR ,20% for normalized enrichment score) among genes associated with drug response in at least one of the two studies. Using IC 50 , most correlations increased slightly, except for 17AAG and PD0332991, with PLX4720 and PD0325901 yielding moderate correlation (Fig. 3c, d , Extended Data Table 1a and Supplementary Fig. 16 ). For AUC, we observed fair correlation for paclitaxel and sorafenib, moderate correlation only for lapatnib, and substantial correlation for PD0325901 and AZD6244 (Fig. 3d , Extended Data Table 1b and Supplementary Fig. 17 ).
These pathway-based correlations are the best observed in our analysis as almost half of the drugs exhibited a correlation greater than 0.5, although they are still quite poor. When stratifying by tissue source, only drugs screened in lung cancer cell lines yielded slightly higher median correlation compared to all tissues combined (Supplementary Figs 18 and 19).
We then performed similar analyses using mutation data of the 64 genes sequenced by both CGP and CCLE (Extended Data Fig. 1g ). We observed that few mutations were significantly associated with drug response (Supplementary Data 11-13), which partly explains the poor correlation between mutation-drug associations (r s , 0.5; Extended Data Fig To test whether genomic data or drug response measures are the likely source of the poor correlations, we used identical (therefore perfectly correlated) gene expression data for the 471 cell lines while keeping the original drug sensitivity measures in each study, but did not find improved correlations for (significant) gene-drug associations (see 'GeneCGP fixed' and 'GeneCCLE fixed' in Fig. 4 ). However, when using identical drug phenotypes with the original gene expression data, correlations significantly increased in all cases (two-sided Kruskal-Wallis test P value ,0.01, see 'DrugCGP fixed' and 'DrugCCLE fixed' in Fig. 4 ) and yielded almost perfect correlation for significant gene-drug associations with AUC (median Spearman's rank correlation .0.83). Results were similar for pathway-drug associations ( Supplementary Fig. 22) . These results clearly demonstrate that the discordance between studies stems from the drug sensitivity measurements.
We also investigated the impact of the choice of pharmacological assay across study and compared CGP and CCLE drug sensitivity data with those published in ref. 10 in a panel of 319 cell lines (the GlaxoSmithKline cell line collection (GSK)). Reference 10 used the same pharmacological assay used by the CCLE (Cell Titer Glo Luminescent Cell Viability Assay kit from Promega), but other parameters in the experimental protocols differ from those in either CGP 6 or CCLE 7 and yet another model was used to estimate IC 50 values (model 205 in XLfit in Microsoft Excel).
Among the 15 drugs shared between CGP and CCLE, only two, lapatinib and paclitaxel, were tested by the GSK study 10 on a common set of 194 cell lines. As might be expected based on the assay used, the GSK data set IC 50 measurements were more consistent with those of CCLE (r s 5 0.42 and 0.36 for lapatinib and paclitaxel, respectively; Supplementary Fig. 23a ) than CGP (r s 5 0.24 and 0.10 for lapatinib and paclitaxel, respectively; Supplementary Fig. 23b ), but here too the overall consistency was rather poor (and similar to the observed consistency between CCLE and CGP).
We then performed the same analysis but focusing on drugs and cell lines shared only by two studies. For lapatinib and paclitaxel, screened by CCLE and the GSK data set in 249 common cell lines, we observed fair to poor correlations (Extended Data Fig. 9a ). Five drugs and 231 cell lines were screened both in CGP and the GSK data set 10 (Extended Data  Fig. 1c) ; for these we observed poor correlation (r s ranging from 0.12 to 0.30; Extended Data Fig. 9b) .
These results add further evidence that the inconsistency between studies stems from the use of different pharmacological assays, but there is no clear evidence to conclude which of the three approaches is more accurate. Indeed, even if we observed perfect correlation between the GSK data set 10 and either the CGP 6 or CCLE 7 drug response assays, all that would indicate is a consistency in measurement, but not necessarily which provided the most meaningful assay of drug response or which could best be translated to in vivo response.
Our analysis of these three large-scale pharmacogenomic studies points to a fundamental problem in assessment of pharmacological drug response. Although gene expression analysis has long been seen as a source of 'noisy' data, extensive work has led to standardized approaches to data collection and analysis and the development of robust platforms for measuring expression levels. This standardization has led to substantially The whiskers extend to the most extreme data point, which is no more than 1.5 times the interquartile range from the box.
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higher quality, more reproducible expression data sets, and this is evident in the CCLE and CGP data where we found excellent correlation between expression profiles in cell lines profiled in both studies.
The poor correlation between drug response phenotypes is troubling and may represent a lack of standardization in experimental assays and data analysis methods. However, there may be other factors driving the discrepancy. As reported by the CGP, there was only a fair correlation (r s , 0.6) between camptothecin IC 50 measurements generated at two sites using matched cell line collections and identical experimental protocols. Although this might lead to speculation that the cell lines could be the source of the observed phenotypic differences, this is highly unlikely as the gene expression profiles are well correlated between studies.
Although our analysis has been limited to common cell lines and drugs between studies, it is not unreasonable to assume that the measured pharmacogenomic response for other drugs and cell lines assayed are also questionable. Ultimately, the poor correlation in these published studies presents an obstacle to using the associated resources to build or validate predictive models of drug response. Because there is no clear concordance, predictive models of response developed using data from one study are almost guaranteed to fail when validated on data from another study 11 , and there is no way with available data to determine which study is more accurate. This suggests that users of both data sets should be cautious in their interpretation of results derived from their analyses.
Clearly the investment in these projects warrants additional work to resolve the discrepancies in drug response phenotype so that the wealth of data that has been generated can be used to its fullest advantage. Our findings support the need for standardization of drug-response measurements or development of new, robust drug sensitivity assays; without such assays, it will not be possible to identify reliably genomic predictors of drug response or to identify effectively a drug's mechanism of action.
METHODS SUMMARY
To ensure reproducibility of our analysis, we developed an automated pipeline in R that can generate all the results, figures and tables of the paper (Supplementary Data 1). Gene expression, mutation and drug sensitivity data were downloaded from the CGP (http://www.cancerrxgene.org), CCLE (http://www.broadinstitute. org/ccle/) and GlaxoSmithKline (http://cbiit.nci.nih.gov/ncip) websites. Drug sensitivity measures, which are IC 50 and AUC values, were set to a common scale (2log 10 (M) for IC50 and [0,1] for AUC) across studies. We assessed the gene/ mutation-drug associations using a linear regression model controlled for tissue source. We used these associations to generate drug-specific gene ranking for pre-ranked gene set enrichment analyses (GSEA 9 ). We used Spearman's rank correlation coefficients (r s ) 12 to assess consistency between CGP and CCLE with qualitative descriptions of r s values associated with intervals: r s , 0.5, poor; 0.5 # r s , 0.6, fair; 0.6 # r s , 0.7, moderate; 0.7 # r s , 0.8, substantial; and r s $ 0.8, almost perfect consistency.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
To ensure reproducibility of our analysis, we developed an automated pipeline in R that can generate all the results, figures and tables of the paper (Supplementary Data 1). Data retrieval and curation. We retrieved and curated data from three large pharmacogenomic studies, namely the Cancer Genome Project (CGP) 6 , the Cancer Cell Line Encyclopedia (CCLE) 7 and the GlaxoSmithKline cell line collection (ref. 10) .
For CGP, gene expression data (raw Affymetrix CEL files) were downloaded from ArrayExpress (http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-783/). Drug sensitivity measurements, mutation data and cell lines annotations were downloaded from the CGP website (http://www.cancerrxgene.org/downloads/). Drug information was collected from Supplementary Information of ref. 6 . Minimum and maximum screening concentrations (mM) for each drug/cell line were extracted from gdsc_compounds_conc_w2.csv available on the CGP website. The natural logarithm of IC 50 measurements were retrieved from column '*_IC_50' of gdsc_manova_input_w2.csv available on the CGP website. The AUC measurements were retrieved from gdsc_manova_input_w2.csv in column '*_AUC'. Coding variants in 68 genes were also extracted from gdsc_manova_input_w2.csv.
For CCLE, gene expression, mutation data cell line annotations and drug information were downloaded from the CCLE website (http://www.broadinstitute. org/ccle). Drug sensitivity data were downloaded from the addendum published by ref. 13 . Screening concentrations (mM) for each drug/cell line were extracted from Supplementary Cell line annotations. Cell line names were harmonized in CGP, CCLE and GSK to match identical cell lines; this was done through manual search over alternative names of cell lines, as reported in the corresponding cell line annotation files and online databases such as hyperCLDB (http://bioinformatics.istge.it/hypercldb/) and BioInformationWeb (http://bioinfoweb.com). We identified 471 cancer cell lines being investigated both in CGP and CCLE, 231 cell lines shared between CGP and GSK, 249 cell lines shared between CCLE and GSK, and 194 cell lines shared by all three studies (Extended Data Fig. 1c) . To annotate the tissue of origin of each cell line, we chose the nomenclature used in CGP; CCLE and GSK tissue type information was therefore updated to follow this nomenclature, which resulted in 24 tissue types. Drug sensitivity data. Drug sensitivity measures, which are IC 50 and AUC values, were set to common scale (2log 10 (M) for IC 50 and [0,1] for AUC) across studies so that high values are representative of cell line sensitivity to drugs. For CGP, extracted IC 50 measures (x) were transformed using 2log 10 (exp(x)/10 6 ), and AUC measures were left untransformed. For CCLE, extracted IC 50 measures (x) were transformed into logarithmic scale, 2log 10 (x/10 6 ), and AUC measures were divided by the number of drug concentrations tested (8) . For GSK, extracted IC 50 measures (x) were transformed using 2log 10 (x/10 3 ). We also discretized the drug sensitivity measures into three categories (resistant, intermediate and sensitive) using the waterfall method described in the CCLE study 7 . The full procedure, as provided by K. Venkatesan (personal communication), is described below. Using this approach we generated drug sensitivity calls for all drugs in CGP and CCLE (Supplementary Tables 1 and 2) . Gene expression data. Raw gene expression profiles (Affymetrix CEL format) for 789 CGP, 1,036 CCLE and 950 cell lines were downloaded, respectively, from ArrayExpress 14 (E-MTAB-783), CCLE (http://www.broadinstitute.org/ccle/) and NCIP (http://cbiit.nci.nih.gov/ncip) websites. Gene expression data were normalized with frozen RMA 15 using the Bioconductor Chip Description File (CDF) definitions (hthgu133a from CGP, and hgu133plus2 for CCLE and GSK). We then used the R package jetset 16 , which maps Affymetrix probe sets to unique Entrez gene IDs by selecting the best probe set for each gene; subsequent analyses were restricted to the 12,153 probe sets common to the CGP, CCLE and GSK arrays. For replicates in CGP and GSK, the CEL files were ordered by hybridization date and the first experiment was selected. To compare gene expression profiles of cell lines 1,000 genes with the most variant expression values were selected in CGP and CCLE data sets (471 shared cell lines; Extended Data Fig. 1d) . Mutation data. Missense mutations in 64 protein-coding genes sequenced in 431 cell lines both in CGP and CCLE were downloaded from their respective website. Similarly to CGP and CCLE studies 6, 7 , mutation data were discretized to represent the presence or absence of missense mutation in a given gene in a given cell line. Gene-drug associations. We assessed the association between gene expression and drug response, referred to as gene-drug association, using a linear regression model controlled for tissue source:
where Y denotes the drug sensitivity variable, G i and T denote the expression of gene i and the tissue type, respectively, and b values are the regression coefficients. The strength of gene-drug association is quantified by b i , above and beyond the relationship between drug sensitivity and tissue source. The variables Y and G are scaled (standard deviation equals to 1) to estimate standardized coefficients from the linear model. Significance of the gene-drug association is estimated by the statistical significance of b i (two-sided t-test). Pathway-drug associations. For each drug, genes were ranked according to the statistical significance of their gene-drug association (Student's t statistic). We then used this drug-specific gene ranking to perform pre-ranked gene set enrichment analyses (GSEA 9 version 2.0.13) to assess enrichment of gene ontology terms 17 curated in MSigDB 9 (c5.all.v4.0.entrez.gmt). Only pathways for which corresponding gene sets contained between 15 genes and 250 genes were considered for further analysis (913 gene sets). We used the resulting normalized enrichment (NES 9 ) scores to quantify the strength of pathway-drug associations. Measures of consistency. We computed Spearman's rank correlation coefficients (r s ) 12 to assess the consistency between CGP and CCLE drug phenotypes (IC 50 and AUC measures), gene/mutation-drug associations (coefficient b) and pathway-drug associations (normalized enrichment scores). We used Cohen's kappa (k) coefficient 18 to assess consistency between CGP and CCLE drug sensitivity calls (resistant, intermediate, sensitive) and mutation data. We used the following qualitative descriptions of correlation coefficient (r s ) values associated with intervals: r s , 0.5, poor consistency; 0.5 # r s , 0.6, fair consistency; 0.6 # r s , 0.7, moderate consistency; 0.7 # r s , 0.8, substantial consistency; and r s $ 0.8, almost perfect consistency. Same qualitative descriptions were used for Cohen's kappa (k) coefficient. i  t  a  z  i  n  a  g  r  O  s  s  a  l  C  )  s  (  t  e  g  r  a  T  d  n  u  o  p  m  o  C  h  c  e  t  n  e  n  e  G  r  o  t  i  b  i  h  n  i  e  s  a  n  i  K  R  F  G  E  b  i  n  i  t  o  l  r  E  Lapatinib  EGFR,HER2  Kinase inhibitor GlaxoSmithKline  r  e  z  i  f  P  r  o  t  i  b  i  h  n  i  e  s  a  n  i  K  T  E  M  -c  2  5  7  5  6  6  -A  H  P  Crizotinib  c-MET,ALK  Kinase inhibitor Pfizer  s  i  t  r  a  v  o  N  r  o  t  i  b  i  h  n  i  e  s  a  n  i  K  K  L  A  4  8 Significance of (positive) Spearman's rank correlation coefficient is reported using the following convention: ***P , 0.001, **P , 0.01, *P , 0.05, NS, P $ 0.05; all P values are one-sided. When less than ten IC50 values were available, correlation coefficient was not computed and was therefore represented by empty cells in the table.
RESEARCH ANALYSIS

